SCHEMBL755273

SCHEMBL755273

CC(=O)N1CCN(C(=O)Nc2ccc(Nc3nc4ccccn4c3-c3cc(N)nc(C)n3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 11/20 0.54
MTOR P42345 11/20 0.54
CDK2 P24941 3/20 0.40
IGF1R P08069 1/20 0.40
TRPV1 Q8NER1 1/20 0.38
LMNA P02545 2/20 0.37
USP7 Q93009 1/20 0.37
GLA P06280 1/20 0.37
NCF1 P14598 1/20 0.37
NAMPT P43490 1/20 0.37
CCNE1 P24864 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CREBBP Q92793 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755278 0.91 PIK3CA (0.53) PIK3CAMTORKDM4EMEN1ALDH1A1
SCHEMBL2786863 0.89 PIK3CA (0.51) PIK3CAMTORCDK2TRPV1LMNA
SCHEMBL753798 0.85 PIK3CA (0.55) PIK3CAMTORTRPV1LMNAKDM4E
SCHEMBL753491 0.85 PIK3CA (0.49) PIK3CAMTORCDK2LMNAUSP7
SCHEMBL2790005 0.85 PIK3CA (0.62) PIK3CAMTORCDK2CCNE1ALDH1A1
SCHEMBL11028397 0.84 PIK3CA (0.59) PIK3CAMTORCDK2LMNAUSP7
SCHEMBL2787772 0.83 PIK3CA (0.51) PIK3CAMTORCDK2NAMPTCCNE1
SCHEMBL2771022 0.82 PIK3CA (0.62) PIK3CAMTORCDK2USP7CCNE1
SCHEMBL750438 0.82 PIK3CA (0.57) PIK3CAMTORCDK2LMNAGLA
SCHEMBL11032907 0.82 PIK3CA (0.54) PIK3CAMTORCDK2CCNE1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885CDK2 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.